Bain Capital Life Sciences Investors, LLC Savara Inc Transaction History
Bain Capital Life Sciences Investors, LLC
- $312 Million
- Q3 2025
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Savara Inc stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 17,600,621 shares of SVRA stock, worth $76.4 Million. This represents 19.88% of its overall portfolio holdings.
Number of Shares
17,600,621
Previous 17,600,621
-0.0%
Holding current value
$76.4 Million
Previous $40.1 Million
54.39%
% of portfolio
19.88%
Previous 12.04%
Shares
5 transactions
Others Institutions Holding SVRA
# of Institutions
133Shares Held
160MCall Options Held
14.3KPut Options Held
24.9K-
Nea Management Company, LLC Timonium, MD24.5MShares$106 Million5.38% of portfolio
-
Vr Adviser, LLC New York, NY12.7MShares$55 Million6.78% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$53.7 Million4.88% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$49.7 Million1.71% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT8.78MShares$38.1 Million1.25% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $495M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.